



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 164833

TO: Jeffrey Parkin
Location: REM-3D39/3C18
Art Unit: 1648
Thursday, September 08, 2005

Case Serial Number: 09/647981

From: Edward Hart
Location: Biotech-Chem Library
REM-1A55
Phone: 571-272-2512

edward.hart@uspto.gov

Search Notes

Examiner Parkin,

Here are the results of the search you requested.

Please feel free to contact me if you have any questions.

Protein Sequence Searches - February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension .rup) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.

This Page Blank (uspto)

STIC-Biotech/ChemLib

16 4833

From: Parkin, Jeffrey
Sent: Tuesday, September 06, 2005 2:23 PM
To: STIC-Biotech/ChemLib
Subject: Sequence Search for U.S. Serial No. 09/647,981

Please search **SEQ ID NO.: 10** from the aforementioned application (U.S. Serial No. 09/647,981; Sia et al.) v. all relevant databases. Place results on **BOTH PAPER and ELECTRONIC FORMAT** (i.e., disk, e-mail, etc.).

Thanks!

JSP
AU 1648
REM 3D39
2-0908

STAFF USE ONLY

Searcher: _____
Searcher Phone: 2-_____
Date Searcher Picked up: 9/7/05
Date Completed: 9/7/05
Searcher Prep/Rev. Time: _____
Online Time: _____

Type of Search

NA#: _____ AA#: 1
Interference: _____ SPDI: _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure#: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable

STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: ASP
WWW/Internet: _____
Other(Specify): _____

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 8, 2005, 03:05:31 ; Search time 165 Seconds
(without alignments)
30.472 Million cell updates/sec

Title: US-09-647-981A-10

Perfect score: 74

Sequence: 1 TPPAYRPPNAPIL 13

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_16Dec04:*
1: Geneseqp1980s:*
2: Geneseqp1990s:*
3: Geneseqp2000s:*
4: Geneseqp2001s:*
5: Geneseqp2002s:*
6: Geneseqp2003as:*
7: Geneseqp2003bs:*
8: Geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	74	100.0	13	2 AAR33501	Aar33501 T helper
2	74	100.0	13	2 AAR78929	Aar78929 HBC 128-1
3	74	100.0	13	2 AAW39439	Aaw39439 Mouse H-2
4	74	100.0	13	2 AAW50117	Aaw50117 Pan DR bi
5	74	100.0	13	3 AAY52556	Aay52556 HBV core
6	74	100.0	13	4 AAG64542	Aag64542 T-helper
7	74	100.0	13	4 AAE02681	Aae02681 Hepatitis
8	74	100.0	13	4 AAE00471	Aae00471 Hepatitis
9	74	100.0	13	4 AAG62426	Aag62426 Immunogen
10	74	100.0	13	4 AAB82775	Aab82775 Hepatitis
11	74	100.0	13	4 AAU00614	Aau00614 H-2 I-Ab
12	74	100.0	13	5 AAU70851	Aau70851 Hepatitis
13	74	100.0	13	5 ABB76787	Abb76787 HBV pepti
14	74	100.0	13	5 ABG62860	Abg62860 Antigenic
15	74	100.0	13	5 ABP52344	Abp52344 TH epitop
16	74	100.0	13	5 ABP52307	Abp52307 T helper
17	74	100.0	13	5 ABP52350	Abp52350 TH epitop
18	74	100.0	13	5 ABP51503	Abp51503 T helper
19	74	100.0	13	6 ABR44095	Abra44095 HBV core
20	74	100.0	13	6 ABP98778	Abp98778 HBV core
21	74	100.0	13	6 AAO22990	Aao22990 p128-40 I
22	74	100.0	13	6 ABU63009	Abu63009 HBV core
23	74	100.0	13	7 ADC21494	Adc21494 Hepatitis
24	74	100.0	13	7 ADC85105	Adc85105 HBV assoc
25	74	100.0	13	7 ADD35647	Add35647 Hepatitis

ALIGNMENTS

RESULT 1

AAR33501
ID AAR33501 standard; peptide; 13 AA.

AC AAR33501;

DT 25-MAR-2003 (revised)

DT 01-JUL-1993 (first entry)

DE T helper peptide HBC 128-140.

KW Hepatitis B virus; HBV; core antigen; MHC class I; chronic; acute;
infection; identification; HLA-restricted.

OS Synthetic.

PN W09303764-Al.

PD 04-MAR-1993.

PF 26-AUG-1992; 92WO-US007218.

PR 26-AUG-1991; 91US-00749568.

PR 29-JAN-1992; 92US-00827682.

PR 27-APR-1992; 92US-00874491.

(CYTE-) CYTEL CORP.

Vitiello MA, Cheesnut RW;

WPI; 1993-093728/11.

Cytotoxic T-lymphocyte stimulating peptide(s) - derived from hepatitis B virus useful for treating, preventing and diagnosing infection.

Disclosure; Page 21; 89pp; English.

This is a T helper epitope peptide, the sequence of which is derived from hepatitis B virus (HBV) core antigen amino acids 128-140. It may be used in a conjugate with cytotoxic T-lymphocyte stimulating (CTL) peptides to enhance an individual's immunity by providing cell-mediated immunity and protective antibodies. (Updated on 25-MAR-2003 to correct PN field.)

SQ Sequence 13 AA;

Query Match 100.0%; Score 74; DB 2; Length 13;

Best Local Similarity 100.0%; Pred. No. 0.0015;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Adg38596 Hepatitis
Adi64650 HBV core
Adk14662 Hepatitis
Adm73996 Specifici
Adn12176 Amino aci
Adr11760 HLA-A2.1
Aaw01776 Hepatitis
Aay52571 HBV core
Aay53554 HBV core
Aay53938 Hepatitis
Aae33958 Hepatitis
Aab67642 Peptide c
Aau70872 Hepatitis
Adc85126 Sequence
Adk14683 Hepatitis
Aap80955 T cell ec
Aar82579 Hepatitis
Aaw05605 Hepatitis
Aay13806 Hepatitis
Aay58772 Unidentif

26 74 100.0 13 7 ADG38596
27 74 100.0 13 7 ADI64650
28 74 100.0 13 8 ADK14662
29 74 100.0 13 8 ADM73996
30 74 100.0 13 8 ADN12176
31 74 100.0 13 8 ADR11760
32 74 100.0 14 3 AAW01776
33 74 100.0 15 2 AAY52571
34 74 100.0 15 2 AAY53554
35 74 100.0 16 6 AAY53938
36 74 100.0 18 6 AAE33958
37 74 100.0 20 4 AAB67642
38 74 100.0 20 5 AAU70872
39 74 100.0 20 7 ADC85126
40 74 100.0 20 8 ADK14683
41 74 100.0 21 1 AAP80955
42 74 100.0 21 2 AAR82579
43 74 100.0 21 2 AAW05605
44 74 100.0 21 2 AAY13806
45 74 100.0 21 3 AAY58772

```

QY      1 TPPAYRPPNPAPIL 13
DB      1 TPPAYRPPNPAPIL 13

RESULT 2
AAR78929
ID AAR78929 standard; peptide; 13 AA.
XX AC AAR78929;
XX DT 25-MAR-2003 (revised)
XX DT 27-MAR-1996 (first entry)
XX DE Hbc 128-140 cytotoxic T lymphocyte epitope.
XX KW Hbc 128-140; cytotoxic T; CTL; epitope; helper T; HTL; cell; lymphocyte;
XX KW antigens; treatment; disease prevention; hepatitis B.
XX OS Hepatitis B virus.
XX PN W09522317-A1.
XX PD 24-AUG-1995.
XX PF 16-FEB-1995; 95WO-US002121.
XX PR 16-FEB-1994; 94US-00197484.
XX PA (CYTE-) CYTEL CORP.
XX PI Vitiello MA, Chesnut RW, Sette AD, Celis E, Grey H;
XX DR WPI; 1995-302545/39.
XX PT Compens. inducing cytotoxic T lymphocyte response to pref. viral,
XX PT bacterial, parasitic or tumour antigens - useful in the treatment and
XX PT prevention of diseases associated with the antigen e.g. hepatitis B.
XX PS Example 4; Page 52; 109pp; English.
XX CC A compen. which induces a cytotoxic T lymphocyte (CTL) response to a
XX CC hepatitis B virus (HBV) antigen (Ag) in a mammal comprises, a HBV CTL Ag
XX CC response inducing peptide (i.e. AAR78929) and a lipid conjugated helper T
XX CC cell inducing peptide. The compen. is useful in the treatment and
XX CC prevention of hepatitis B. (Updated on 25-MAR-2003 to correct PI field.)
XX SQ Sequence 13 AA;

Query Match 100.0%; Score 74; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0015;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TPPAYRPPNPAPIL 13
DB      1 TPPAYRPPNPAPIL 13

RESULT 3
AAW39439
ID AAW39439 standard; peptide; 13 AA.
XX AC AAW39439;
XX DT 11-JUN-1998 (first entry)
XX DE Mouse H-2 I-Ab-restricted HBV core antigen-derived T helper epitope.
XX KW T cell epitope; immune response; human leukocyte antigen; HLA Class I;
XX KW vaccine; immunogenic; major histocompatibility complex; MHC; B cell;
XX KW disease; anti-tumour; anti-viral.
XX

Query Match 100.0%; Score 74; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0015;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TPPAYRPPNPAPIL 13
DB      1 TPPAYRPPNPAPIL 13

RESULT 4
AAW50117
ID AAW50117 standard; peptide; 13 AA.
XX AC AAW50117;
XX DT 30-JUN-1998 (first entry)
XX DE Pan DR binding peptide (14).
XX KW Pan DR binding peptide; antigen binding site; MHC molecule; DR locus.
XX OS Synthetic.
XX PN US5736142-A.
XX PD 07-APR-1998.
XX PF 14-SEP-1994; 94US-00305871.
XX PR 14-SEP-1993; 93US-00121101.
XX PA (CYTE-) CYTEL CORP.

```

```

OS Synthetic.
OS Mus sp.
XX WO9741440-A1.
XX 06-NOV-1997.
XX 28-APR-1997; 97WO-NL000229.
XX 26-APR-1996; 96EP-00201145.
XX 23-DEC-1996; 96EP-00203670.
XX (UYLE-) RIJKSUNIV LEIDEN.
XX PA (SCIS-) SCI SEED CAPITAL INVESTMENTS BV.
XX PI Van Der Burg SH, Kast WM, Toes REM, Offringa R, Melief CJM;
XX WPI; 1997-549891/50.
XX Method of selecting T cell peptide epitope(s) - by measuring the
XX PT stability of HLA class I-peptide complexes on intact B cells.
XX PS Example 2; Page 21; 109pp; English.
XX CC Peptides AAW39430-W39734 are used in a novel method for the selection of
XX CC immunogenic T-cell peptide epitopes present in polypeptide antigens.
XX CC Peptide AAW39439 is a mouse H-2 I-Ab restricted HBV core antigen-derived
XX CC T helper epitope which is injected into HLA-A*0201Kb transgenic mice. The
XX CC method involves the identification of peptide sequences capable of
XX CC binding to an HLA (human leukocyte antigen) class I molecule and
XX CC measuring the binding of this epitope peptide to the HLA class I peptide.
XX CC The stability of binding of the peptide and MHC (major histocompatibility
XX CC complex) class I molecule is measured on intact human B cells carrying
XX CC the MHC molecule at their cell surfaces. The method can be used to select
XX CC peptide epitopes for generating vaccines against a disease associated
XX CC with the polypeptide, e.g. cancers or AIDS. The peptide epitopes are
XX CC especially T-cell peptide epitopes with strong anti-tumour and anti-viral
XX CC immune responses
XX SQ Sequence 13 AA;

Query Match 100.0%; Score 74; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0015;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TPPAYRPPNPAPIL 13
DB      1 TPPAYRPPNPAPIL 13

```


PT HIV vaccines.

XX

PS

XX Example 7; Page 42; 383pp; English.

XX

CC The invention relates to identification of cytotoxic T cell lymphocyte (CTL) epitopes (AAM22116-AAM23484) that generate anti-HIV activity. CTL are a major protective mechanism against viral diseases. Antibodies may neutralise extracellular human immunodeficiency virus (HIV) and limit or prevent infection of cells in the host, but CTL will limit viral production by killing the cell. The CTL epitopes are useful in medicine, CC in the manufacture of vaccines or diagnostic agents. The present sequence is that of a T-helper epitope peptide useful to the invention

XX

XX Sequence 13 AA;

SQ

Query Match 100.0%; Score 74; DB 4; Length 13;

Best Local Similarity 100.0%; Pred. No. 0.0015;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13

DB 1 TPPAYRPPNPAPIL 13

RESULT 7

AAE02681

ID AAE02681 standard; peptide; 13 AA.

XX

AC AAE02681;

XX

DT 06-AUG-2001 (first entry)

XX

DE Hepatitis B virus HBVc helper peptide.

XX

KW Cytostatic; antibacterial; antifungal; gene therapy; vaccine; antiviral; tumour; epitope; glycoprotein; hepatitis B virus; HBV; immune response; CTL; cytotoxic T lymphocyte; HLA; human leucocyte antigen.

KW

KW

XX

OS Hepatitis B virus.

XX

FN WO200127291-A1.

XX

PD 19-APR-2001.

XX

PF 29-SEP-2000; 2000WO-EF009902.

XX

PR 12-OCT-1999; 99US-0158356P.

XX

PA (INSP) INST PASTEUR.

XX

PI First H, Lemonnier F, Langlade-Demoyen P;

XX

DR WPI; 2001-282038/29.

XX

PT New polynucleotide comprising at least one viral, fungal, bacterial, or tumor epitope of an antigen, capable of inducing a cellular response.

XX

PS Example 1; Page 23; 70pp; English.

XX

CC The invention relates to polynucleotide containing at least a part of the coding sequence of the middle glycoprotein of hepatitis B virus (HBV) in which is inserted a DNA sequence coding for an epitope comprising at least one viral, fungal, bacterial, or tumour epitope of an antigen, CC capable of inducing a cellular response. Nucleic acids and compositions of the invention are useful for inducing in vivo a CTL (cytotoxic T lymphocyte) response against several epitopes of one or more, bacterial, viral, fungal, or tumour antigens. A composition of the invention CC produces an immune response against HIV antigen and are used in the production of vaccines. The polynucleotides of the invention are also used in gene therapy. The present sequence is hepatitis B virus helper peptide. This peptide is co-injected with human epitopes in order to CC elicit HLA (human leucocyte antigen) -A2.1-restricted CTL response in mice

XX

XX Sequence 13 AA;

SQ

Query Match 100.0%; Score 74; DB 4; Length 13;

Best Local Similarity 100.0%; Pred. No. 0.0015;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13

DB 1 TPPAYRPPNPAPIL 13

RESULT 8

AAE00471

ID AAE00471 standard; peptide; 13 AA.

XX

AC AAE00471;

XX

DT 19-JUN-2001 (first entry)

XX

DE Hepatitis B virus core (HBVc) tumour epitopic peptide.

XX

KW Tumour epitope; cytostatic; immunostimulant; gene therapy; middle glycoprotein; Hepatitis B virus core; cytotoxic response; immune response; cytotoxic T lymphocyte; CTL; HBVc; HLA; human leucocyte antigen.

KW

XX

OS Hepatitis B virus.

XX

FN WO200123577-A2.

XX

PD 05-APR-2001.

XX

PF 29-SEP-2000; 2000WO-EP009900.

XX

PR 30-SEP-1999; 99US-0156945P.

XX

PA (INSP) INST PASTEUR.

XX

PI Firat H, Lemonnier F, Langlade-Demoyen P, Michel M, Suhrbier AA;

XX

DR WPI; 2001-266164/27.

XX

PT Novel polynucleotide having DNA sequence encoding tumor antigen epitope inserted in part of coding sequence of middle glycoprotein of hepatitis B virus, used to induce immune response against tumor-specific antigen.

XX

PS Example 1; Page 13; 36pp; English.

XX

CC The present invention relates to an isolated or purified polynucleotide containing a DNA sequence coding for at least one tumour epitope of a tumour antigen inserted into part of the coding sequence of the middle glycoprotein of the Hepatitis B virus (HBV). The polynucleotide is useful for optionally evaluating cytotoxic responses in the individual's lymphocyte population. It induces an immune response against at least one tumour specific antigen or tissue specific antigen. The vector comprising the polynucleotide induces in vivo, cellular and/or humoral immune response. The composition comprising the polynucleotide induces in vivo, CC cytotoxic T lymphocyte (CTL) against one or more antigens or epitopes present on the hybrid protein. The polynucleotide is also useful in gene therapy. The present sequence is a Hepatitis B virus core (HBVc) tumour epitopic peptide. This peptide elicits HLA (human leucocyte antigen) -A2.1 - restricted CTL response in mice

XX

XX Sequence 13 AA;

SQ

Query Match 100.0%; Score 74; DB 4; Length 13;

Best Local Similarity 100.0%; Pred. No. 0.0015;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13

DB 1 TPPAYRPPNPAPIL 13


```

RESULT 9
AAG62426
ID AAG62426 standard; peptide; 13 AA.
XX
AC AAG62426;
XX
DT 03-SEP-2001 (first entry)
XX
XX Immunogenic peptide HBV core SEQ ID 30.
XX
DE Class I epitope; immunogenic; heteroclitic analogue; immune response;
KW antigen display; viral disease; cancer.
XX
OS Synthetic.
XX
XX WO200136452-A2.
PN
XX
XX 25-MAY-2001.
PD
XX
XX 20-NOV-2000; 2000WO-US031856.
PF
XX
XX 18-NOV-1999; 99US-0166529P.
PR
XX 06-OCT-2000; 2000US-0239008P.
XX
XX (EPIM-) EPIMMUNE INC.
PA
XX
XX Tangri S, Sette A, Ishioka G;
PI
XX WPI; 2001-355609/37.
DR
XX
XX Enhancing immunogenicity of peptide containing class I epitope, useful
PT for treating cancer, comprises providing (semi-)conservative amino acid
PT substitutions at specified positions of these epitopes.
XX
XX Disclosure; Fig 1A; 96pp; English.
XX
XX This invention relates to a method of enhancing the immunogenicity of a
CC peptide, where the peptide contains a class I epitope. The invention
CC includes methods for preparing peptides containing epitopes which have
CC enhanced ability to effect an immune response (compared to wild-type
CC epitopes). The peptides are referred to as heteroclitic analogues. The
CC method is useful for eliciting an immune response by contacting CTLs with
CC the immunogenically enhanced peptide in vitro in the presence of an
CC antigen presenting cell, or by administering to a subject a nucleic acid
CC molecule comprising a nucleotide sequence encoding the peptide. The
CC peptides are useful as reagents to evaluate an immune response and the
CC efficacy of the vaccine, and for making antibodies. The heteroclitic
CC analogues are useful in immunological compositions for the treatment of
CC viral diseases, cancer, and other conditions which are characterised by
CC displayed antigens on target cells. The present sequence represents a
CC class I epitope which may be used in the method of the invention
XX
SQ Sequence 13 AA;
Query Match 100.0%; Score 74; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0015;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TPPAYRPPNAPIL 13
Db 1 TPPAYRPPNAPIL 13
|||||
AAU00614
ID AAU00614 standard; peptide; 13 AA.
XX
AC AAU00614;
XX
XX 12-SEP-2001 (first entry)
DT
DE H-2 I-Ab-restricted HBV core antigen-derived T helper epitope.
XX
XX Human; MUC1; antigenic peptide; major histocompatibility complex; MHC-I;
KW glycoprotein; cytotoxic T lymphocytes; T cell response; cancer; vaccine;
KW cancer gene therapy; diagnosis; treatment; inflammatory disorder; HBV;
KW organ transplant rejection; graft versus host disease.

```

```

XX Hepatitis B core antigen peptide.
DE
XX Telomerase reverse transcriptase; hTERT; human; cytotoxic T lymphocyte;
KW major histocompatibility complex; cancer; tumour;
KW human leucocyte antigen; HLA-A2.1; HBVc; vaccine.
XX
OS Hepatitis B virus.
PN WO200160391-A1.
XX
XX 23-AUG-2001.
XX
XX 15-FEB-2001; 2001WO-US005143.
XX
XX 15-FEB-2000; 2000US-0182685P.
PR
XX 15-FEB-2001; 2001US-00182685.
XX
XX (REGC ) UNIV CALIFORNIA.
PA
XX
XX Zanetti M;
PI
XX WPI; 2001-536552/59.
DR
XX
XX Vaccine for initiating and enhancing a cytotoxic T lymphocyte response,
PT for treating cancers or tumors or for inducing immune response against
PT tumors, comprises a telomerase reverse transcriptase peptide.
XX
XX Example 1; Page 12; 52pp; English.
XX
XX The present sequence is that of a hepatitis B virus core antigen (HBVc)
CC peptide comprising amino acid residues 128-140. The peptide was used to
CC immunise HHD mice and results were compared with those obtained using
CC human telomerase reverse transcriptase (hTERT) HLA-A2.1+ restricted
CC peptide p540 (see AAB82772). The induction of CTL responses in vitro and
CC in vivo, and the susceptibility to lysis of tumour cells of various
CC origins by hTERT CTL suggest that hTERT could serve as a universal cancer
CC vaccine for humans. A claimed universal vaccine for treating tumours of
CC any origin comprises at least 1 hTERT peptide. The peptide is 7-15 amino
CC acid residues in length and may be modified to enhance binding to the
CC major histocompatibility complex. Also claimed is a method for inducing
CC and enhancing a CTL response against cancer cells, involving harvesting
CC blood leucocytes, pulsing with hTERT, and contacting cancer cells with the
CC pulsed leucocytes. A method for targeting CTL to tumour cells is also
CC claimed, and involves administering a hTERT peptide to a mammal,
CC especially a cancer patient. (Updated on 06-AUG-2003 to correct OS
CC field.)
XX
SQ Sequence 13 AA;
Query Match 100.0%; Score 74; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0015;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TPPAYRPPNAPIL 13
Db 1 TPPAYRPPNAPIL 13
|||||
AAU00614
ID AAU00614 standard; peptide; 13 AA.
XX
AC AAU00614;
XX
XX 12-SEP-2001 (first entry)
DT
DE H-2 I-Ab-restricted HBV core antigen-derived T helper epitope.
XX
XX Human; MUC1; antigenic peptide; major histocompatibility complex; MHC-I;
KW glycoprotein; cytotoxic T lymphocytes; T cell response; cancer; vaccine;
KW cancer gene therapy; diagnosis; treatment; inflammatory disorder; HBV;
KW organ transplant rejection; graft versus host disease.

```

```

XX Hepatitis B virus.
OS
XX WO200118035-A2.
XX
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-EP008761.
XX
XX 08-SEP-1999; 99GB-00021242.
XX
XX 10-SEP-1999; 99EP-00402237.
XX
XX 03-MAR-2000; 2000US-0187215P.
XX
XX (TRGE ) TRANSGENE SA.
XX
XX (IMCR ) IMPERIAL CANCER RES TECHNOLOGY LTD.
XX
XX Taylor-Papadimitriou J, Heukamp LC, Offringa R, Melief CJM;
XX Acres B, Thomas M;
XX
XX WPI; 2001-235187/24.
XX
XX New antigenic polypeptides of MUC-1 protein which activate cytotoxic T
XX lymphocyte proteins and their analogs, useful for identifying a major
XX histocompatibility complex class I restricted T cell response and for
XX diagnosing cancer.
XX
XX Example 5; Page 42; 81pp; English.
XX
XX The sequence represents an H-2 I-Ab-restricted hepatitis B virus (HBV)
XX core antigen-derived T helper epitope used in testing of human MUC1
XX polypeptide derivatives through a cytotoxic T lymphocyte (CTL) assay.
XX Derivative antigenic peptides of MUC1 protein bind at least one major
XX histocompatibility complex class I (MHC-I) glycoprotein, which activates
XX cytotoxic T lymphocytes to induce a protective response against tumours.
XX Diagnosis of cancer involves determining the presence or absence in a
XX host cell of MHC class I restricted T cell response to a MUC1 derivative,
XX where the presence of the MHC class I restricted T cell response
XX indicates that the host has cancer. Measurement of the level of MHC class
XX I restricted T cell response is also useful to monitor the severity of
XX cancer, a larger response indicating a more severe cancer. MUC1
XX derivatives are useful in cancer therapy and to follow MUC1 specific
XX immune responses in patients during the course of disease and/or
XX treatment. MUC1 DNA is useful in cancer gene therapy, vaccination and
XX diagnosis. Compositions of the sequences are used in vaccines and
XX treatments against cancer or diseases caused by an immune response, such
XX as an inflammatory disorder, organ transplant rejection or graft versus
XX host disease
XX
XX Sequence 13 AA;
XX
XX Query Match 100.0%; Score 74; DB 4; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 0.0015;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 TPPAYRPPNAPIL 13
XX |||||
XX Db 1 TPPAYRPPNAPIL 13
XX
XX RESULT 12
XX AAU70851
XX ID AAU70851 standard; peptide; 13 AA.
XX
XX AC AAU70851;
XX
XX 14-FEB-2002 (first entry)
XX
XX Hepatitis B virus antigen binding partner #83.
XX
XX Hepatitis B virus; virucide; immunomodulator; hepatotropic; HBV;
XX antiinflammatory; HBV core antigen; HBcAg; HBV E antigen; HBeAg;
XX B cell mediated processing; T cell proliferation; cytokine production;
XX immune system response.

```

```

XX Synthetic.
XX
XX WO200181421-A2.
XX
XX 01-NOV-2001.
XX
XX 20-APR-2001; 2001WO-IB000844.
XX
XX 21-APR-2000; 2000US-00556605.
XX
XX (TRIP-) TRIPEP AB.
XX
XX Sallberg M;
XX
XX WPI; 2002-055347/07.
XX
XX Novel peptide that binds to hepatitis B virus core or E antigen, useful
XX for treating and preventing hepatitis B virus infection.
XX
XX Example 6; Page 28; 82pp; English.
XX
XX The invention relates to an isolated or purified peptide (I) which binds
XX Hepatitis B virus (HBV) core antigen (HBcAg) or HBV E antigen (HBeAg).
XX (I) is useful for treating or preventing Hepatitis B virus (HBV)
XX infection, by identifying a subject in need of a molecule that inhibits
XX HBV infection, and providing the subject with (I). (I) is also useful for
XX determining the presence of HBV in a biological sample, and for
XX inhibiting B cell mediated processing and uptake of HBcAg and/or HBeAg,
XX by determining whether (I) inhibits B cell mediated processing and uptake
XX of HBcAg and/or HBeAg by performing an assay of T cell proliferation or
XX cytokine production. (I) is also useful for modulating an immune system
XX response. (I) is useful as a template for a design of synthetic molecules
XX including peptides, derivatives or modified peptides, peptidomimetics and
XX chemicals. (I) is also useful as biotechnological tool, diagnostic
XX reagent and as active ingredient in pharmaceuticals. (I) is also useful
XX as detection reagents in conventional immunohistochemical techniques, as
XX diagnostic reagents to detect HBV in biological sample, and to determine
XX the efficacy of an HBV treatment protocol by monitoring the levels of
XX HBcAg and/or HBeAg during and after treatment. AAU70766-AAU70876
XX represent Hepatitis B virus (HBV) core antigen (HBcAg) or HBV E antigen
XX (HBeAg) binding partners as described in the invention
XX
XX Sequence 13 AA;
XX
XX Query Match 100.0%; Score 74; DB 5; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 0.0015;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 TPPAYRPPNAPIL 13
XX |||||
XX Db 1 TPPAYRPPNAPIL 13
XX
XX RESULT 13
XX ABB76787
XX ID ABB76787 standard; peptide; 13 AA.
XX
XX AC ABB76787;
XX
XX 31-MAY-2002 (first entry)
XX
XX HBV peptide 128-140.
XX
XX Antiviral; anti-HIV; cytostatic; epitope; HLA A2.1;
XX human leukocyte antigen; immunotherapy; cancer; viral infection; vaccine.
XX
XX Unidentified.
XX
XX FR2812087-A1.
XX
XX 25-JAN-2002.
XX

```

```

PF 21-JUL-2000; 2000FR-00009591.
XX
PR 21-JUL-2000; 2000FR-00009591.
XX
PA (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX
PI Kosmatopoulos K, Tourdot S, Scardino A, Gross DA;
XX
DR WPI; 2002-189846/25.
XX
XX Identifying subdominant or cryptic epitopes, useful in immunotherapy of
PT cancer and viral infection, comprises testing modified, non-immunogenic
PT peptides for induction of cytotoxic T cells.
XX
PS Example 1; Page 14; 62pp; French.
XX
XX The present invention relates to subdominant/cryptic epitopes that are
CC presented by HLA (human leukocyte antigen) Class I molecule A2.1. The
CC epitopes or chimeric polypeptides containing them and nucleic acid
CC encoding them are useful for preventative or curative immunotherapy of
CC cancer and viral infections, particularly where used as vaccines. The
CC present peptide was used to illustrate the invention
XX
XX Sequence 13 AA;
SQ
Query Match 100.0%; Score 74; DB 5; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0015;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TPPAYRPPNPAPIL 13
DB 1 TPPAYRPPNPAPIL 13
| | | | | | | | | | | | |
RESULT 14
ABG62860
ID ABG62860 standard; peptide; 13 AA.
XX
AC ABG62860;
XX
XX 21-AUG-2002 (first entry)
XX
DE Antigenic domain peptide from a Hepatitis B virus protein.
XX
KW Ligand/receptor specificity exchanger; antibody; pathogen receptor;
KW bacterial infection; viral infection; yeast infection; cancer;
KW parasitic infection; fungal infection; proliferation; antibacterial;
KW virucide; cytostatic; antifungal; antigenic domain.
XX
OS Hepatitis B virus.
XX
XX WO200224887-A2.
XX
XX 28-MAR-2002.
XX
XX 19-SEP-2001; 2001WO-IB002327.
XX
XX 19-SEP-2000; 2000US-00664025.
XX
XX (TRIP-) TRIPEP AB.
XX
XX Sallberg M, Flock J;
XX
XX WPI; 2002-489707/52.
XX
XX Novel ligand/receptor specificity exchanger that redirects antibodies to
PT receptors on pathogen or tumor cell, has specificity domain having ligand
PT for receptor, and antigenic domain having epitope of pathogen or toxin.
XX
XX Claim 14; Page 14; 79pp; English.
XX
XX The present invention relates to ligand/receptor specificity exchangers
CC comprising at least one specificity domain comprising a ligand for a

```

```

CC receptor, and at least one antigenic domain joined to the specificity
CC domain, where the antigenic domain comprises an epitope of a pathogen or
CC toxin. The ligand/receptor specificity exchangers redirect antibodies to
CC receptors present on pathogens. They are useful for preventing and
CC treating human diseases such as bacterial, viral, yeast, parasitic and
CC fungal infections, and cancer. These compositions act by inhibiting
CC proliferation of pathogens, or cancer cells. One of the prophylactic
CC applications of the ligand/receptor specificity exchangers includes
CC coating or crosslinking it to a medical device or implant which include
CC implantable medical devices that tend to serve as foci for infection by a
CC number of bacterial species. ABG62853-ABG62869 represent antigenic domain
CC peptides used in the methods of the present invention
XX
XX Sequence 13 AA;
SQ
Query Match 100.0%; Score 74; DB 5; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0015;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TPPAYRPPNPAPIL 13
DB 1 TPPAYRPPNPAPIL 13
| | | | | | | | | | | | |
RESULT 15
ABP52344
ID ABP52344 standard; peptide; 13 AA.
XX
AC ABP52344;
XX
XX 17-OCT-2002 (first entry)
XX
DE TH epitope.
XX
KW Cytotoxic T lymphocyte; CTL; T helper; MAGE3; cytotoxic T cell response;
KW tumour; immune response; cancer; vaccine; antibody.
XX
OS Synthetic.
XX
XX WO200258728-A2.
XX
XX 01-AUG-2002.
XX
XX 28-JAN-2002; 2002WO-GB000354.
XX
XX 26-JAN-2001; 2001GB-00002145.
XX
XX (SCAN-) SCANCELL LTD.
XX
XX (CANC-) CANCER RES CAMPAIGN TECHNOLOGY.
XX
XX Durrant LG, Parsons T, Robins A;
XX
XX WPI; 2002-608418/65.
XX
XX Use of polypeptides and nucleic acids encoding the polypeptides, in
PT manufacturing medicament for stimulating a cytotoxic T cell response and
PT for preventing or treating cancer, e.g. colorectal, lung, breast or
PT ovarian cancer.
XX
XX Example 11; Page 45; 87pp; English.
XX
XX The present invention describes the use of a polypeptide (I) in the
CC manufacture of a medicament for stimulating a cytotoxic T cell response,
CC where (I) comprises a first portion comprising the part of human Fc that
CC binds to CD64 and a second portion comprising one or more heterologous T
CC cell epitopes. Also described is a method of stimulating a cytotoxic T
CC cell response in a patient such as a mammal, preferably human, by
CC administering (I) to the patient. (I) has cytostatic activity and can be
CC used in vaccine production. (I) and the nucleic acid encoding (I) are
CC useful in the manufacture of a medicament for stimulating cytotoxic T
CC cell response. The medicament is useful for preventing and/or treating
CC cancer, e.g. colorectal, lung, breast, gastric or ovarian cancer. The
CC medicament stimulates cytotoxic and helper T cell responses. The

```

CC antibodies are useful as vaccines to stimulate helper and cytotoxic T
CC cell responses. The polypeptides and nucleic acids are useful in
CC optimising immunisation schedules for enhancing a protective immune
CC response against cancer. The present sequence represents a TH epitope
CC which is used in an example from the present invention
XX

SQ Sequence 13 AA;

Query Match 100.0%; Score 74; DB 5; Length 13;
Best Local Similarity 100.0%; Pred. NO. 0.0015;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13
|||
Db 1 TPPAYRPPNAPIL 13
|||

Search completed: September 8, 2005, 03:21:19
Job time : 168 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 8, 2005, 03:14:31; Search time 39 Seconds
(without alignments)
32.072 Million cell updates/sec

Title: US-09-647-981A-10

Perfect score: 74

Sequence: 1 TPPAYRPPNPAPIL 13

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: PIR 79:*

2: pir1:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	74	100.0	183	1 NKVLA2	core antigen - hep
2	74	100.0	183	1 NKVLCF	core antigen - hep
3	74	100.0	183	2 S53181	core antigen - hep
4	74	100.0	183	2 S53260	core antigen - hep
5	74	100.0	183	2 S53214	core antigen - hep
6	74	100.0	183	2 S53175	core antigen - hep
7	74	100.0	183	2 S53152	core antigen - hep
8	74	100.0	183	2 S53221	core antigen - hep
9	74	100.0	183	2 S53140	core antigen - hep
10	74	100.0	183	2 S53232	core antigen - hep
11	74	100.0	183	2 S20755	core antigen - hep
12	74	100.0	183	2 S53172	core antigen - hep
13	74	100.0	183	2 S53166	core antigen - hep
14	74	100.0	183	2 S53129	core antigen - hep
15	74	100.0	183	2 S53189	core antigen - hep
16	74	100.0	183	2 S53169	core antigen - hep
17	74	100.0	183	2 S53186	core antigen - hep
18	74	100.0	183	2 S53194	core antigen - hep
19	74	100.0	183	2 S53270	core antigen - hep
20	74	100.0	183	2 S53247	core antigen - hep
21	74	100.0	184	2 S53146	core antigen - hep
22	74	100.0	195	1 NKVLH3	core antigen - hep
23	74	100.0	211	1 NKVLA1	e antigen precursor
24	74	100.0	212	1 NKVLA4	e antigen precursor
25	74	100.0	212	1 NKVLAH	e antigen precursor
26	74	100.0	212	1 NKVLBH	e antigen precursor
27	74	100.0	212	1 NKVLJ1	e antigen precursor
28	74	100.0	212	1 NKVLJ2	e antigen precursor
29	74	100.0	212	2 S53238	e antigen precursor

ALIGNMENTS

RESULT 1

NKVLA2

core antigen - hepatitis B virus (subtype adyw)

C:Species: hepatitis B virus, HBV

A:Variety: subtype adyw

C:Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Jul-2004

C:Accession: B93217; A03711

R:Pasek, M.; Goto, T.; Gilbert, W.; Zink, B.; Schaller, H.; MacKay, P.; Leadbetter, G.;

Nature 282, 575-579, 1979

A:Title: Hepatitis B virus genes and their expression in E. coli.

A:Reference number: A93217; MUID:81012115; PMID:399329

A:Accession: B93217

A:Molecule type: DNA

A:Residues: 1-183 <PAS>

A:Cross-references: UNIPROT:P03147; GB:J02202; NID:G329637; PIDN:AAA5486.1; PID:G32963

A:Experimental source: subtype adyw

A:Note: due to a stop codon between the alternative initiators the e antigen precursor,

C:Genetics:

A:Gene: C

C:Superfamily: hepatitis B virus core antigen

C:Keywords: core protein

F:1-183/Product: core antigen #status predicted <MAT>

Query Match 100.0%; Score 74; DB 1; Length 183;
Best Local Similarity 100.0%; Pred. No. 0.00067; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13

Db 128 TPPAYRPPNPAPIL 140

RESULT 2

NKVLCF

core antigen - hepatitis B virus (strain LSH, chimpanzee)

N:Alternate names: HBC antigen

C:Species: hepatitis B virus, HBV

A:Variety: strain LSH, chimpanzee

C:Date: 30-Jun-1989 #sequence_revision 30-Jun-1989 #text_change 09-Jul-2004

C:Accession: A28885

R:Vaadin, M.; Wolstenholme, A.J.; Taiquaye, K.N.; Zuckerman, A.J.; Harrison, T.J.

J. Gen. Virol. 69, 1383-1389, 1988

A:Title: The complete nucleotide sequence of the genome of a hepatitis B virus isolated

A:Reference number: A92796; MUID:88258473; PMID:2838576

A:Accession: A28885

A:Molecule type: DNA

A:Residues: 1-183 <VAU>

A:Cross-references: UNIPROT:P12901; EMBL:D00220; NID:G221505; PIDN:BAA00157.1; PID:G2215

A:Experimental source: strain LSH, chimpanzee

A:Note: due to a stop codon between the alternative initiators the e antigen precursor,

C:Genetics:

A:Gene: C

C:Superfamily: hepatitis B virus core antigen
C:Keywords: core protein

Query Match 100.0%; Score 74; DB 1; Length 183;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13
|||||
Db 128 TPPAYRPPNAPIL 140

RESULT 3

S53181
core antigen - hepatitis B virus
N:Alternate names: HBC antigen
N:Contains: core antigen
C:Species: hepatitis B virus, HBV
C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004
C:Accession: S53181; S53291
R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.
submitted to the EMBL Data Library, March 1995
A:Reference number: S53112
A:Accession: S53181
A:Molecule type: DNA
A:Residues: 1-183 <LAI>
A:Cross-references: UNIPROT:Q67997; EMBL:X85279; NID:g736073; PIDN:CAAS59583.1; PID:g736073
A:Experimental source: isolate patient Bitti'89
A:Note: due to a stop codon between the alternative initiators the e antigen precursor
A:Accession: S53291
A:Molecule type: DNA
A:Residues: 1-20, 'T', 22-37, 'L', 39, 'D', 41-57, 'E', 59-76, 'Q', 78-83, 'L', 85-86, 'N', 88-146, 'S'
A:Cross-references: EMBL:X85263; NID:g736232; PIDN:CAAS59538.1; PID:g736235
A:Experimental source: isolate patient Amoroso'89
A:Note: due to a stop codon between the alternative initiators the e antigen precursor
C:Genetics:
A:Gene: C
C:Superfamily: hepatitis B virus core antigen
C:Keywords: core protein

Query Match 100.0%; Score 74; DB 2; Length 183;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13
|||||
Db 128 TPPAYRPPNAPIL 140

RESULT 4

S53260
core antigen - hepatitis B virus (isolate patient Mannoni-3'94)
N:Alternate names: HBC antigen
N:Contains: core antigen
C:Species: hepatitis B virus, HBV
A:Variety: isolate patient Mannoni-3'94
C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004
C:Accession: S53260
R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.
submitted to the EMBL Data Library, March 1995
A:Reference number: S53112
A:Accession: S53260
A:Molecule type: DNA
A:Residues: 1-183 <LAI>
A:Cross-references: UNIPROT:Q68060; EMBL:X85311; NID:g736187; PIDN:CAAS59555.1; PID:g736187
A:Experimental source: isolate patient Mannoni-3'94
A:Note: due to a stop codon between the alternative initiators the e antigen precursor
C:Genetics:
A:Gene: C
C:Superfamily: hepatitis B virus core antigen
C:Keywords: core protein

Query Match 100.0%; Score 74; DB 2; Length 183;

Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13
|||||
Db 128 TPPAYRPPNAPIL 140

RESULT 5

S53214
core antigen - hepatitis B virus (isolate patient Castag-2'86)
N:Alternate names: HBC antigen
N:Contains: core antigen
C:Species: hepatitis B virus, HBV
A:Variety: isolate patient Castag-2'86
C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004
C:Accession: S53214
R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.
submitted to the EMBL Data Library, March 1995
A:Reference number: S53112
A:Accession: S53214
A:Molecule type: DNA
A:Residues: 1-183 <LAI>
A:Cross-references: UNIPROT:Q68023; EMBL:X85292; NID:g736120; PIDN:CAAS59614.1; PID:g736120
A:Experimental source: isolate patient Castag-2'86
A:Note: due to a stop codon between the alternative initiators the e antigen precursor
C:Genetics:
A:Gene: C
C:Superfamily: hepatitis B virus core antigen
C:Keywords: core protein

Query Match 100.0%; Score 74; DB 2; Length 183;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13
|||||
Db 128 TPPAYRPPNAPIL 140

RESULT 6

S53175
core antigen - hepatitis B virus (isolate patient Boi'90)
N:Alternate names: HBC antigen
N:Contains: core antigen
C:Species: hepatitis B virus, HBV
A:Variety: isolate patient Boi'90
C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004
C:Accession: S53175
R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.
submitted to the EMBL Data Library, March 1995
A:Reference number: S53112
A:Accession: S53175
A:Molecule type: DNA
A:Residues: 1-183 <LAI>
A:Cross-references: UNIPROT:Q67993; EMBL:X85277; NID:g736065; PIDN:CAAS59577.1; PID:g736065
A:Experimental source: isolate patient Boi'90
A:Note: due to a stop codon between the alternative initiators the e antigen precursor
C:Genetics:
A:Gene: C
C:Superfamily: hepatitis B virus core antigen
C:Keywords: core protein

Query Match 100.0%; Score 74; DB 2; Length 183;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13
|||||
Db 128 TPPAYRPPNAPIL 140

RESULT 7

S53152
core antigen - hepatitis B virus (isolate patient Tufariello'89)
N:Alternate names: HBC antigen
N:Contains: core antigen
C:Species: hepatitis B virus, HBV
A:Variety: isolate patient Tufariello'89
C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004
C:Accession: S53152
R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.
submitted to the EMBL Data Library, March 1995
A:Reference number: S53112
A:Accession: S53152
A:Molecule type: DNA
A:Residues: 1-183 <LAI>
A:Cross-references: UNIPROT:Q67973; EMBL:X85269; NID:G736033; PIDN:CAA59556.1; PID:G736033
A:Experimental source: isolate patient Tufariello'89
A:Note: due to a stop codon between the alternative initiators the e antigen precursor
C:Genetics:
A:Gene: C
C:Superfamily: hepatitis B virus core antigen
C:Keywords: core protein

Query Match 100.0%; Score 74; DB 2; Length 183;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
|||||
Db 128 TPPAYRPPNPAPIL 140

RESULT 8
S53221
core antigen - hepatitis B virus (isolate patient Giulio'92)
N:Alternate names: HBC antigen
N:Contains: core antigen
C:Species: hepatitis B virus, HBV
A:Variety: isolate patient Giulio'92
C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004
C:Accession: S53221
R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.
submitted to the EMBL Data Library, March 1995
A:Reference number: S53112
A:Accession: S53221
A:Molecule type: DNA
A:Residues: 1-183 <LAI>
A:Cross-references: UNIPROT:Q68027; EMBL:X85258; NID:G736127; PIDN:CAA59525.1; PID:G736127
A:Experimental source: isolate patient Giulio'92
A:Note: due to a stop codon between the alternative initiators the e antigen precursor
C:Genetics:
A:Gene: C
C:Superfamily: hepatitis B virus core antigen
C:Keywords: core protein

Query Match 100.0%; Score 74; DB 2; Length 183;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
|||||
Db 128 TPPAYRPPNPAPIL 140

RESULT 9
S53140
core antigen - hepatitis B virus (isolate patient Frailis'92)
N:Alternate names: HBC antigen
N:Contains: core antigen
C:Species: hepatitis B virus, HBV
A:Variety: isolate patient Frailis'92
C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004
C:Accession: S53140
R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.

submitted to the EMBL Data Library, March 1995
A:Reference number: S53112
A:Accession: S53140
A:Molecule type: DNA
A:Residues: 1-183 <LAI>
A:Cross-references: UNIPROT:Q67964; EMBL:X85265; NID:G736017; PIDN:CAA59544.1; PID:G736017
A:Experimental source: isolate patient Frailis'92
A:Note: due to a stop codon between the alternative initiators the e antigen precursor
C:Genetics:
A:Gene: C
C:Superfamily: hepatitis B virus core antigen
C:Keywords: core protein

Query Match 100.0%; Score 74; DB 2; Length 183;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
|||||
Db 128 TPPAYRPPNPAPIL 140

RESULT 10
S53232
core antigen - hepatitis B virus (isolate patient Dettori-2'87)
N:Alternate names: HBC antigen
N:Contains: core antigen
C:Species: hepatitis B virus, HBV
A:Variety: isolate patient Dettori-2'87
C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004
C:Accession: S53232
R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.
submitted to the EMBL Data Library, March 1995
A:Reference number: S53112
A:Accession: S53232
A:Molecule type: DNA
A:Residues: 1-183 <LAI>
A:Cross-references: UNIPROT:Q68037; EMBL:X85299; NID:G736146; PIDN:CAA59629.1; PID:G736146
A:Experimental source: isolate patient Dettori-2'87
A:Note: due to a stop codon between the alternative initiators the e antigen precursor
C:Genetics:
A:Gene: C
C:Superfamily: hepatitis B virus core antigen
C:Keywords: core protein

Query Match 100.0%; Score 74; DB 2; Length 183;
Best Local Similarity 100.0%; Pred. No. 0.00067;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
|||||
Db 128 TPPAYRPPNPAPIL 140

RESULT 11
S20755
core antigen - hepatitis B virus
N:Alternate names: HBC antigen
N:Contains: core antigen
C:Species: hepatitis B virus, HBV
C:Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 09-Jul-2004
C:Accession: S20755; S53134
R:Lai, M.E.; Mazzoleni, A.P.; Balestrieri, A.; Melis, A.; Porru, A.
submitted to the EMBL Data Library, March 1992
A:Description: Sequence analysis of HBV genomes isolated from patients with HBsAg negative
A:Reference number: S20745
A:Accession: S20755
A:Molecule type: DNA
A:Residues: 1-183 <LAI>
A:Cross-references: UNIPROT:Q67880; EMBL:X65259; NID:G59439; PIDN:CAA46359.1; PID:G59443
A:Experimental source: subtype ayw, patient E
A:Note: due to a stop codon between the alternative initiators the e antigen precursor
R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.

submitted to the EMBL Data Library, March 1995

A:Reference number: S53112

A:Accession: S53134

A:Molecule type: DNA

A:Residues: 1-7,'E','9-11','S','13-16','SF','19-24','PS','27-33','S','35-37','P','39','D','41-48','T',

A:Cross-references: EMBL:X85255; NID:g736009; PIDN:CAAS9517.1; PID:g736012

A:Experimental source: isolate patient Tarcisloc'92

A>Note: due to a stop codon between the alternative initiators the e antigen precursor

C:Genetics:

A:Gene: C

C:Superfamily: hepatitis B virus core antigen

C:Keywords: core protein

Query Match 100.0%; Score 74; DB 2; Length 183;

Best Local Similarity 100.0%; Pred. No. 0.00067;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13

|||||

Db 128 TPPAYRPPNAPIL 140

RESULT 12

S53172 core antigen - hepatitis B virus (isolate patient Urtis'89)

N:Alternate names: HBC antigen

N:Contains: core antigen

C:Species: hepatitis B virus, HBV

A:Variety: isolate patient Urtis'89

C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004

C:Accession: S53172

R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.

submitted to the EMBL Data Library, March 1995

A:Reference number: S53112

A:Accession: S53172

A:Molecule type: DNA

A:Residues: 1-183 <LAI>

A:Cross-references: UNIPROT:Q67991; EMBL:X85276; NID:g736061; PIDN:CAAS9574.1; PID:g7360

A:Experimental source: isolate patient Urtis'89

A>Note: due to a stop codon between the alternative initiators the e antigen precursor

C:Genetics:

A:Gene: C

C:Superfamily: hepatitis B virus core antigen

C:Keywords: core protein

Query Match

Best Local Similarity 100.0%; Score 74; DB 2; Length 183;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13

|||||

Db 128 TPPAYRPPNAPIL 140

RESULT 13

S53166

core antigen - hepatitis B virus (isolate patient Tedde'89)

N:Alternate names: HBC antigen

N:Contains: core antigen

C:Species: hepatitis B virus, HBV

A:Variety: isolate patient Tedde'89

C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004

C:Accession: S53166

R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.

submitted to the EMBL Data Library, March 1995

A:Reference number: S53112

A:Accession: S53166

A:Molecule type: DNA

A:Residues: 1-183 <LAI>

A:Cross-references: UNIPROT:Q67986; EMBL:X85274; NID:g736053; PIDN:CAAS9568.1; PID:g7360

A:Experimental source: isolate patient Tedde'89

A>Note: due to a stop codon between the alternative initiators the e antigen precursor

C:Genetics:

A:Gene: C

C:Superfamily: hepatitis B virus core antigen

C:Keywords: core protein

Query Match 100.0%; Score 74; DB 2; Length 183;

Best Local Similarity 100.0%; Pred. No. 0.00067;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13

|||||

Db 128 TPPAYRPPNAPIL 140

RESULT 14

S53129

core antigen - hepatitis B virus

N:Alternate names: HBC antigen

N:Contains: core antigen

C:Species: hepatitis B virus, HBV

C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004

C:Accession: S53129

R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.

submitted to the EMBL Data Library, March 1995

A:Reference number: S53112

A:Accession: S53129

A:Molecule type: DNA

A:Residues: 1-183 <LAI>

A:Cross-references: UNIPROT:Q67946; EMBL:X85254; NID:g736003; PIDN:CAAS9512.1; PID:g7360

C:Genetics:

A:Gene: C

C:Superfamily: hepatitis B virus core antigen

C:Keywords: core protein

Query Match

Best Local Similarity 100.0%; Score 74; DB 2; Length 183;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13

|||||

Db 128 TPPAYRPPNAPIL 140

RESULT 15

S53189

core antigen - hepatitis B virus (isolate patient Serra'89)

N:Alternate names: HBC antigen

N:Contains: core antigen

C:Species: hepatitis B virus, HBV

A:Variety: isolate patient Serra'89

C:Date: 08-Jul-1995 #sequence_revision 03-Aug-1995 #text_change 09-Jul-2004

C:Accession: S53189

R:Lai, M.E.; Mazzoleni, A.P.; Porru, A.; Balestrieri, A.

submitted to the EMBL Data Library, March 1995

A:Reference number: S53112

A:Accession: S53189

A:Molecule type: DNA

A:Residues: 1-183 <LAI>

A:Cross-references: UNIPROT:Q68003; EMBL:X85282; NID:g736084; PIDN:CAAS9591.1; PID:g7360

A:Experimental source: isolate patient Serra'89

A>Note: due to a stop codon between the alternative initiators the e antigen precursor

C:Genetics:

A:Gene: C

C:Superfamily: hepatitis B virus core antigen

C:Keywords: core protein

Query Match

Best Local Similarity 100.0%; Score 74; DB 2; Length 183;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13

|||||

Db 128 TPPAYRPPNAPIL 140

Search completed: September 8, 2005, 03:24:55
Job time : 40 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 8, 2005, 03:06:11; Search time 168 Seconds
(without alignments)
39.625 Million cell updates/sec

Title: US-09-647-981A-10
Perfect score: 74
Sequence: 1 TPPAYRPPNAPIL 13

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Uniprot_03: *
1: uniprot_spot: *
2: uniprot_trembl: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	74	100.0	96	2 Q77BF4	Q77bf4 hepatitis b
2	74	100.0	96	2 Q77BF6	Q77bf6 hepatitis b
3	74	100.0	96	2 Q77BF8	Q77bf8 hepatitis b
4	74	100.0	96	2 Q77BG0	Q77bg0 hepatitis b
5	74	100.0	96	2 Q77BG1	Q77bg1 hepatitis b
6	74	100.0	96	2 Q77BG3	Q77bg3 hepatitis b
7	74	100.0	96	2 Q77BG4	Q77bg4 hepatitis b
8	74	100.0	96	2 Q77BG5	Q77bg5 hepatitis b
9	74	100.0	96	2 Q77BG7	Q77bg7 hepatitis b
10	74	100.0	96	2 Q77BG9	Q77bg9 hepatitis b
11	74	100.0	96	2 Q77BH1	Q77bh1 hepatitis b
12	74	100.0	96	2 Q77BH3	Q77bh3 hepatitis b
13	74	100.0	96	2 Q9YJM3	Q9Yjm3 hepatitis b
14	74	100.0	96	2 Q9YQ42	Q9Yq42 hepatitis b
15	74	100.0	113	2 Q80J61	Q80j61 hepatitis b
16	74	100.0	130	2 Q8JSV0	Q8jsv0 hepatitis b
17	74	100.0	130	2 Q8JSV1	Q8jsv1 hepatitis b
18	74	100.0	130	2 Q8JSV2	Q8jsv2 hepatitis b
19	74	100.0	130	2 Q8JSV3	Q8jsv3 hepatitis b
20	74	100.0	130	2 Q8JSV4	Q8jsv4 hepatitis b
21	74	100.0	130	2 Q8JSV5	Q8jsv5 hepatitis b
22	74	100.0	130	2 Q8JSV6	Q8jsv6 hepatitis b
23	74	100.0	130	2 Q8JSV7	Q8jsv7 hepatitis b
24	74	100.0	130	2 Q8JSV9	Q8jsv9 hepatitis b
25	74	100.0	130	2 Q8JWS0	Q8jws0 hepatitis b
26	74	100.0	130	2 Q8JWS1	Q8jws1 hepatitis b
27	74	100.0	130	2 Q8JWS2	Q8jws2 hepatitis b
28	74	100.0	130	2 Q8JWS3	Q8jws3 hepatitis b
29	74	100.0	130	2 Q8JWS4	Q8jws4 hepatitis b
30	74	100.0	130	2 Q8JWS5	Q8jws5 hepatitis b
31	74	100.0	130	2 Q8JWS6	Q8jws6 hepatitis b

32	74	100.0	130	2 Q8JSW7	Q8jsw7 hepatitis b
33	74	100.0	130	2 Q8JSW8	Q8jsw8 hepatitis b
34	74	100.0	130	2 Q8JSW9	Q8jsw9 hepatitis b
35	74	100.0	130	2 Q8JSX0	Q8jsx0 hepatitis b
36	74	100.0	130	2 Q8JSX1	Q8jsx1 hepatitis b
37	74	100.0	130	2 Q8JSX2	Q8jsx2 hepatitis b
38	74	100.0	130	2 Q8JSX3	Q8jsx3 hepatitis b
39	74	100.0	130	2 Q8JSX4	Q8jsx4 hepatitis b
40	74	100.0	130	2 Q8JSX5	Q8jsx5 hepatitis b
41	74	100.0	130	2 Q8QP11	Q8qp11 hepatitis b
42	74	100.0	130	2 Q8QP13	Q8qp13 hepatitis b
43	74	100.0	130	2 Q8QP14	Q8qp14 hepatitis b
44	74	100.0	130	2 Q8QP15	Q8qp15 hepatitis b
45	74	100.0	130	2 Q8QP16	Q8qp16 hepatitis b

ALIGNMENTS

RESULT 1					
Q77BF4 PRELIMINARY; PRT; 96 AA.					
AC	Q77BF4				
DT	05-JUL-2004 (Tremblrel. 27, Created)				
DT	05-JUL-2004 (Tremblrel. 27, Last sequence update)				
DE	Core antigen (Fragment)				
OS	Hepatitis B virus.				
OC	Viruses; Retrovird viruses; Hepadnaviridae; Orthohepadnavirus.				
OX	NCBI_TaxID=10407;				
RN	[1]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN=Genotype D; TISSUE=Blood;				
RX	MEDLINE=20381124; PubMed=10921962;				
RA	Petrosillo N., Ippolito G., Solfrosi L., Varaldo P.E., Clementi M.,				
RA	Manzin A.;				
RT	"Molecular epidemiology of an outbreak of fulminant hepatitis B.";				
RL	J. Clin. Microbiol. 38:2975-2981(2000).				
DR	EMBL; AJ010005; CAA08960.1; -				
DR	InterPro; IPR002006; Hepatitis core.				
DR	Pfam; PF00906; Hepatitis_core; 1.				
FT	NON_TER 1				
SQ	SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;				
Query Match 100.0%; Score 74; DB 2; Length 96;					
Best Local Similarity 100.0%; Pred. No. 0.0036;					
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	1 TPPAYRPPNAPIL 13				
Db	41 TPPAYRPPNAPIL 53				
RESULT 2					
Q77BF6 PRELIMINARY; PRT; 96 AA.					
AC	Q77BF6				
DT	05-JUL-2004 (Tremblrel. 27, Created)				
DT	05-JUL-2004 (Tremblrel. 27, Last sequence update)				
DE	Core antigen (Fragment)				
OS	Hepatitis B virus.				
OC	Viruses; Retrovird viruses; Hepadnaviridae; Orthohepadnavirus.				
OX	NCBI_TaxID=10407;				
RN	[1]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN=Genotype D; TISSUE=Blood;				
RX	MEDLINE=20381124; PubMed=10921962;				
RA	Petrosillo N., Ippolito G., Solfrosi L., Varaldo P.E., Clementi M.,				
RA	Manzin A.;				
RT	"Molecular epidemiology of an outbreak of fulminant hepatitis B.";				
RL	J. Clin. Microbiol. 38:2975-2981(2000).				
DR	EMBL; AJ010005; CAA08958.1; -				

```

DR InterPro: IPR002006; Hepatitis_core.
DR Pfam: PF00906; Hepatitis_core; 1.
SQ NON_TER 1
SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNPAPIL 13
Db 41 TPPAYRPPNPAPIL 53

RESULT 3
Q77BG0
ID Q77BF8 PRELIMINARY; PRT; 96 AA.
AC Q77BF8
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solforsio L., Varaldo P.E., Clementi M.,
RA Manzin A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ010004; CAA08956.1; -.
DR InterPro: IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON_TER 1
SQ SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNPAPIL 13
Db 41 TPPAYRPPNPAPIL 53

RESULT 4
Q77BG0
ID Q77BG0 PRELIMINARY; PRT; 96 AA.
AC Q77BG0
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solforsio L., Varaldo P.E., Clementi M.,
RA Manzin A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ010003; CAA08954.1; -.
DR InterPro: IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON_TER 1
SQ SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNPAPIL 13
Db 41 TPPAYRPPNPAPIL 53

RESULT 5
Q77BG1
ID Q77BG1 PRELIMINARY; PRT; 96 AA.
AC Q77BG1
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solforsio L., Varaldo P.E., Clementi M.,
RA Manzin A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ010002; CAA08952.1; -.
DR InterPro: IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON_TER 1
SQ SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNPAPIL 13
Db 41 TPPAYRPPNPAPIL 53

RESULT 6
Q77BG3
ID Q77BG3 PRELIMINARY; PRT; 96 AA.
AC Q77BG3
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solforsio L., Varaldo P.E., Clementi M.,
RA Manzin A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ010000; CAA08948.1; -.
DR InterPro: IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON_TER 1
SQ SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNPAPIL 13
Db 41 TPPAYRPPNPAPIL 53

```

```

Db 41 TPPAYRPPNPAPIL 53
|||||
RESULT 7
Q77BG4 PRELIMINARY; PRT; 96 AA.
ID Q77BG4;
AC Q77BG4;
DT 05-JUL-2004 (TREMBlrel. 27, Created)
DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solforsì L., Varaldo P.E., Clementi M.,
RT Manzin A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ009997; CAA08946.1;
DR InterPro; IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON TER 1
SQ A SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
|||||
Db 41 TPPAYRPPNPAPIL 53

RESULT 8
Q77BG5 PRELIMINARY; PRT; 96 AA.
ID Q77BG5;
AC Q77BG5;
DT 05-JUL-2004 (TREMBlrel. 27, Created)
DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solforsì L., Varaldo P.E., Clementi M.,
RT Manzin A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ009998; CAA08944.1;
DR InterPro; IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON TER 1
SQ SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
|||||
Db 41 TPPAYRPPNPAPIL 53

RESULT 9
Q77BH1 PRELIMINARY; PRT; 96 AA.
ID Q77BH1;
AC Q77BH1;
DT 05-JUL-2004 (TREMBlrel. 27, Created)
DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)

```

```

Q77BG7 PRELIMINARY; PRT; 96 AA.
ID Q77BG7;
AC Q77BG7;
DT 05-JUL-2004 (TREMBlrel. 27, Created)
DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solforsì L., Varaldo P.E., Clementi M.,
RT Manzin A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ009997; CAA08942.1;
DR InterPro; IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON TER 1
SQ SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
|||||
Db 41 TPPAYRPPNPAPIL 53

RESULT 10
Q77BG9 PRELIMINARY; PRT; 96 AA.
ID Q77BG9;
AC Q77BG9;
DT 05-JUL-2004 (TREMBlrel. 27, Created)
DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solforsì L., Varaldo P.E., Clementi M.,
RT Manzin A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ009996; CAA08940.1;
DR InterPro; IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON TER 1
SQ SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
|||||
Db 41 TPPAYRPPNPAPIL 53

RESULT 11
Q77BH1 PRELIMINARY; PRT; 96 AA.
ID Q77BH1;
AC Q77BH1;
DT 05-JUL-2004 (TREMBlrel. 27, Created)
DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)

```

```

DT 05-JUL-2004 (TReMBLrel. 27, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solfrosi L., Varaldo P.E., Clementi M.,
RA Manzini A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ009995; CAA08938.1; -;
DR InterPro; IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON_TER 1
SQ SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
Db 41 TPPAYRPPNAPIL 53

RESULT 12
Q77BH3
ID Q77BH3 PRELIMINARY; PRT; 96 AA.
DT 05-JUL-2004 (TReMBLrel. 27, Created)
DT 05-JUL-2004 (TReMBLrel. 27, Last sequence update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solfrosi L., Varaldo P.E., Clementi M.,
RA Manzini A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ009994; CAA08936.1; -;
DR InterPro; IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON_TER 1
SQ SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
Db 41 TPPAYRPPNAPIL 53

RESULT 13
Q9YJM3
ID Q9YJM3 PRELIMINARY; PRT; 96 AA.
DT 01-MAY-1999 (TReMBLrel. 10, Created)
DT 01-MAY-1999 (TReMBLrel. 10, Last sequence update)
DT 01-MAY-2004 (TReMBLrel. 26, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;

```

```

RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solfrosi L., Varaldo P.E., Clementi M.,
RA Manzini A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ010007; CAA08962.1; -;
DR InterPro; IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON_TER 1
SQ SEQUENCE 96 AA; 11443 MW; FBA862E745196B9E CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
Db 41 TPPAYRPPNAPIL 53

RESULT 14
Q9YQ42
ID Q9YQ42 PRELIMINARY; PRT; 96 AA.
DT 01-MAY-1999 (TReMBLrel. 10, Created)
DT 01-MAY-1999 (TReMBLrel. 10, Last sequence update)
DT 01-OCT-2002 (TReMBLrel. 22, Last annotation update)
DE Core antigen (Fragment).
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Genotype D; TISSUE=Blood;
RX MEDLINE=20381124; PubMed=10921962;
RA Petrosillo N., Ippolito G., Solfrosi L., Varaldo P.E., Clementi M.,
RA Manzini A.;
RT "Molecular epidemiology of an outbreak of fulminant hepatitis B.";
RL J. Clin. Microbiol. 38:2975-2981(2000).
DR EMBL; AJ010001; CAA08950.1; -;
DR InterPro; IPR002006; Hepatitis_core.
DR Pfam; PF00906; Hepatitis_core; 1.
FT NON_TER 1
SQ SEQUENCE 96 AA; 11428 MW; D46972F6440979BE CRC64;

Query Match 100.0%; Score 74; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 0.0036;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
Db 41 TPPAYRPPNAPIL 53

RESULT 15
Q80J61
ID Q80J61 PRELIMINARY; PRT; 113 AA.
AC Q80J61;
DT 01-JUN-2003 (TReMBLrel. 24, Created)
DT 01-JUN-2003 (TReMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Core protein.
OS Hepatitis B virus.
OC Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
OX NCBI_TaxID=10407;
RN [1]
RP SEQUENCE FROM N.A.
RX PubMed=15215682; DOI=10.1023/B:VIRU.0000032787.77837.09;
RA Luo K., Liu Z., He H., Peng J., Liang W., Dai W., Hou J.;
RT "The putative recombination of hepatitis B virus genotype B with pre-

```

RT c/c region of genotype C.";
RL Virus Genes 29:31-41(2004).
DR EMBL; AY217370; AAC63544.1; --
DR InterPro; IPR002006; Hepatitis core.
DR Pfam; PF00906; Hepatitis core; 2.
SQ SEQUENCE 113 AA; 13068 MW; 3A0E460F2038C680 CRC64;

Query Match 100.0%; Score 74; DB 2; Length 113;
Best Local Similarity 100.0%; Pred. No. 0.0043;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
||| ||||| |||||
Db 58 TPPAYRPPNAPIL 70

Search completed: September 8, 2005, 03:24:10
Job time : 169 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 8, 2005, 02:55:25 ; Search time 42 Seconds
(without alignments)
23.106 Million cell updates/sec

Title: US-09-647-981A-10
Perfect score: 74
Sequence: 1 TPPAYRPPNAPIL 13

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*

1: /cgn2_6/prodata/1/iaa/5A COMB.pep.*
2: /cgn2_6/prodata/1/iaa/5B COMB.pep.*
3: /cgn2_6/prodata/1/iaa/6A COMB.pep.*
4: /cgn2_6/prodata/1/iaa/6B COMB.pep.*
5: /cgn2_6/prodata/1/iaa/PCTUS COMB.pep.*
6: /cgn2_6/prodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	74	100.0	13	1	US-08-305-871A-14
2	74	100.0	13	3	US-08-464-496-19
3	74	100.0	13	4	US-08-788-822A-16
4	74	100.0	13	4	US-08-197-484-113
5	74	100.0	13	4	US-09-311-784A-49
6	74	100.0	13	4	US-09-664-945-50
7	74	100.0	13	5	PCT-US92-07218-19
8	74	100.0	13	5	PCT-US95-02121-113
9	74	100.0	13	5	PCT-US95-16415-9
10	74	100.0	14	4	US-09-311-784A-124
11	74	100.0	15	3	US-08-737-896-7
12	74	100.0	15	5	PCT-US96-09951-7
13	74	100.0	21	3	US-09-100-409A-45
14	74	100.0	21	4	US-09-701-623C-69
15	74	100.0	21	5	PCT-US95-13841-13
16	74	100.0	23	3	US-08-464-496-20
17	74	100.0	23	4	US-08-197-484-114
18	74	100.0	23	5	PCT-US92-07218-20
19	74	100.0	23	5	PCT-US95-02121-114
20	74	100.0	26	3	US-08-464-496-21
21	74	100.0	26	4	US-08-197-484-115
22	74	100.0	26	5	PCT-US92-07218-21
23	74	100.0	26	5	PCT-US95-02121-115
24	74	100.0	80	4	US-09-311-784A-22
25	74	100.0	118	4	US-09-311-784A-8
26	74	100.0	119	4	US-09-311-784A-10
27	74	100.0	136	4	US-09-311-784A-12

28	74	100.0	138	4	US-09-311-784A-4	Sequence 4, Appli
29	74	100.0	152	4	US-09-311-784A-20	Sequence 20, Appli
30	74	100.0	154	3	US-08-968-747-1	Sequence 1, Appli
31	74	100.0	155	3	US-08-968-747-17	Sequence 17, Appli
32	74	100.0	159	3	US-08-445-585-3	Sequence 3, Appli
33	74	100.0	161	3	US-08-968-747-19	Sequence 19, Appli
34	74	100.0	164	4	US-09-311-784A-18	Sequence 18, Appli
35	74	100.0	183	3	US-08-968-747-20	Sequence 20, Appli
36	74	100.0	183	3	US-09-248-588-2	Sequence 2, Appli
37	74	100.0	183	3	US-09-248-588-4	Sequence 4, Appli
38	74	100.0	183	5	PCT-US96-10602-12	Sequence 12, Appli
39	74	100.0	185	1	US-07-739-642-2	Sequence 2, Appli
40	74	100.0	185	1	US-07-739-642-4	Sequence 4, Appli
41	74	100.0	185	1	US-07-739-642-8	Sequence 8, Appli
42	74	100.0	185	1	US-07-739-642-10	Sequence 10, Appli
43	74	100.0	185	1	US-07-739-643-2	Sequence 2, Appli
44	74	100.0	185	1	US-07-739-643-4	Sequence 4, Appli
45	74	100.0	185	1	US-07-739-643-8	Sequence 8, Appli

ALIGNMENTS

RESULT 1
US-08-305-871A-14
; Sequence 14, Application US/08305871A
; Patent No. 5736142
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Gaeta, Federico
; APPLICANT: Grey, Howard M.
; APPLICANT: Sidney, John
; APPLICANT: Alexander, Jeffrey L.
; TITLE OF INVENTION: Alteration of Immune Response Using Pan
; TITLE OF INVENTION: DR-Binding Peptides
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/305,871A
; FILING DATE: 14-SEP-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/121,101
; FILING DATE: 14-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Bastian, Kevin L.
; REGISTRATION NUMBER: 34,774
; REFERENCE/DOCKET NUMBER: 14137-0062-10
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-305-871A-14
Query Match 100.0%; Score 74; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00025;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
|||||
Db 1 TPPAYRPPNAPIL 13

RESULT 2

US-08-464-496-19
; Sequence 19, Application US/08464496
; Patent No. 6322789
; GENERAL INFORMATION:
; APPLICANT: Epimmune, Inc.
; APPLICANT: Vitiello, Maria
; APPLICANT: Chesnut, Robert
; TITLE OF INVENTION: HLA-RESTRICTED HEPATITIS B VIRUS CTL
; FILE REFERENCE: 39963-20001.13
; CURRENT APPLICATION NUMBER: US/08/464,496
; CURRENT FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: 07/935,811
; PRIOR FILING DATE: 1992-08-26
; PRIOR APPLICATION NUMBER: 07/874,491
; PRIOR FILING DATE: 1992-04-27
; PRIOR APPLICATION NUMBER: 07/827,682
; PRIOR FILING DATE: 1992-01-29
; PRIOR APPLICATION NUMBER: 07/749,568
; PRIOR FILING DATE: 1991-08-26
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: T helper epitope HBC 128-140
US-08-464-496-19

Query Match 100.0%; Score 74; DB 3; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00025;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
|||||
Db 1 TPPAYRPPNAPIL 13

RESULT 3

US-08-788-822A-16
; Sequence 16, Application US/08788822A
; Patent No. 6413935
; GENERAL INFORMATION:
; APPLICANT: Alexander, Jeffrey L.
; APPLICANT: Defrees, Shawn
; APPLICANT: Sette, Alessandro
; TITLE OF INVENTION: Induction of Immune Response Against
; TITLE OF INVENTION: Desired Determinants
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/788,822A
; FILING DATE: 23-JAN-1997

; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/010,510
; FILING DATE: 24-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Bastian, Kevin L.
; REGISTRATION NUMBER: 34,774
; REFERENCE/DOCKET NUMBER: 014137-009210US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-788-822A-16

Query Match 100.0%; Score 74; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00025;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
|||||
Db 1 TPPAYRPPNAPIL 13

RESULT 4

US-08-197-484-113
; Sequence 113, Application US/08197484
; Patent No. 6419931
; GENERAL INFORMATION:
; APPLICANT: VITIELLO, Maria A.
; APPLICANT: CHESTNUT, Robert W.
; APPLICANT: SETTE, Alessandro D.
; APPLICANT: CELIS, Esteban
; APPLICANT: GRAY, Howard
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
; TITLE OF INVENTION: CTL IMMUNITY
; NUMBER OF SEQUENCES: 153
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Khourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/197,484
; FILING DATE: 16-FEB-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/935,811
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/874,491
; FILING DATE: 27-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,682
; FILING DATE: 29-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,568
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990

```
; REFERENCE/DOCKET NUMBER: 14137-26-4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 457-9600
; TELEFAX: (206) 623-6793
; INFORMATION FOR SEQ ID NO: 113:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-197-484-113

Query Match          100.0%; Score 74; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00025;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
Db 1 TPPAYRPPNPAPIL 13

RESULT 5
US-09-311-784A-49
; Sequence 49, Application US/09311784A
; Patent No. 6534482
; GENERAL INFORMATION:
; APPLICANT: Fikes, John D.
; APPLICANT: Hermanson, Gary G.
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn Y.
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert W.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Expression Vectors for Stimulating an
; TITLE OF INVENTION: Immune Response and Methods of Using the Same
; FILE REFERENCE: 39963-20022.01
; CURRENT APPLICATION NUMBER: US/09/311,784A
; CURRENT FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: US 60/085,751
; PRIOR FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 49
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: residues 128-141 of HBV core antigen (HBVcore 128)
US-09-311-784A-49

Query Match          100.0%; Score 74; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00025;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
Db 1 TPPAYRPPNPAPIL 13

RESULT 6
US-09-664-945-50
; Sequence 50, Application US/09664945
; Patent No. 6660842
; GENERAL INFORMATION:
; APPLICANT: Matti Sallberg
; TITLE OF INVENTION: LIGAND/RECEPTOR SPECIFICITY EXCHANGERS
; TITLE OF INVENTION: THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN
; FILE REFERENCE: TRIPEP.007CP3
; CURRENT APPLICATION NUMBER: US/09/664,945
; CURRENT FILING DATE: 2000-09-19
; PRIOR APPLICATION NUMBER: 09/532,106
; PRIOR FILING DATE: 2000-03-21

; REFERENCE/DOCKET NUMBER: 14137-26-4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 457-9600
; TELEFAX: (206) 623-6793
; INFORMATION FOR SEQ ID NO: 113:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-197-484-113

Query Match          100.0%; Score 74; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00025;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
Db 1 TPPAYRPPNPAPIL 13

RESULT 7
PCT-US92-07218-19
; Sequence 19, Application PC/TUS9207218
; GENERAL INFORMATION:
; APPLICANT: Vitello, Maria A.
; APPLICANT: Chesnut, Robert W.
; TITLE OF INVENTION: HLA-RESTRICTED HEPATITIS B VIRUS CTL
; TITLE OF INVENTION: EPITOPES
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Steuart Street Tower
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/07218
; FILING DATE: 19920826
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,568
; FILING DATE: 26-AUG-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,682
; FILING DATE: 29-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/874,491
; FILING DATE: 27-APR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14137-26-3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: AMINO ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
```

PCT-US92-07218-19

Query Match 100.0%; Score 74; DB 5; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00025;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
|||||
Db 1 TPPAYRPPNAPIL 13

RESULT 8

PCT-US95-02121-113
; Sequence 113, Application PC/TUS9502121
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
; NUMBER OF SEQUENCES: 153
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/02121
; FILING DATE: 16-FEB-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/197,484
; FILING DATE: 16-FEB-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/935,811
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/874,491
; FILING DATE: 27-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,682
; FILING DATE: 29-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,568
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14137-26-4PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 467-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 113:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
; PCT-US95-02121-113

Query Match 100.0%; Score 74; DB 5; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00025;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
|||||
Db 1 TPPAYRPPNAPIL 13

RESULT 9

PCT-US95-16415-9
; Sequence 9, Application PC/TUS9516415
; GENERAL INFORMATION:
; APPLICANT: The Scripps Research Institute

; TITLE OF INVENTION: IN VIVO ACTIVATION OF TUMOR-SPECIFIC
; TITLE OF INVENTION: CYTOTOXIC T CELLS
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: The Scripps Research Institute
; STREET: 10666 North Torrey Pines Road, TPC-8
; CITY: La Jolla
; STATE: California
; COUNTRY: US
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/16415
; FILING DATE: 13-DEC-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/355,558
; FILING DATE: 14-DEC-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Logan, April C.
; REGISTRATION NUMBER: 33,950
; REFERENCE/DOCKET NUMBER: 433.1PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 554-2937
; TELEFAX: (619) 554-6312
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US95-16415-9

Query Match 100.0%; Score 74; DB 5; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.00025;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
|||||
Db 1 TPPAYRPPNAPIL 13

RESULT 10

US-09-311-784A-124
; Sequence 124, Application US/09311784A
; Patent No. 6534482
; GENERAL INFORMATION:
; APPLICANT: Fikes, John D.
; APPLICANT: Hermanson, Gary G.
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn Y.
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert W.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Expression Vectors for Stimulating an
; FILE REFERENCE: 39963-20022.01
; CURRENT APPLICATION NUMBER: US/09/311,784A
; CURRENT FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: US 60/085,751
; PRIOR FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 124
; LENGTH: 14
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HBVcore128

US-09-311-784A-124

Query Match 100.0%; Score 74; DB 4; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.00026;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTPAYRPPNAPIL 13
Db 1 TTPAYRPPNAPIL 13

RESULT 11

US-08-737-896-7
Sequence 7, Application US/08737896
Patent No. 6168804
GENERAL INFORMATION:
APPLICANT: Samuel, John
APPLICANT: Kwon, Glen S.
TITLE OF INVENTION: METHOD FOR ELICITING THI-SPECIFIC
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 4225 Executive Square, Suite 1400
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: FastSeq for Windows Version 2.0b
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/737,896
FILING DATE: 24-SEP-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/480,499
FILING DATE: 07-JUN-1996
APPLICATION NUMBER: PCT/US96/09551
FILING DATE: 07-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: Haile, Lisa A.
REGISTRATION NUMBER: 38,347
REFERENCE/DOCKET NUMBER: 07254/037001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/678-5070
TELEFAX: 619/678-5099
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
CLONE: HbcAg

Query Match 100.0%; Score 74; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.00028;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTPAYRPPNAPIL 13
Db 3 TTPAYRPPNAPIL 15

RESULT 12

PCT-US96-09951-7
Sequence 7, Application PC/TUS9609951
GENERAL INFORMATION:
APPLICANT: The Governors of the University of Alberta
TITLE OF INVENTION: A METHOD FOR ELICITING A THI-SPECIFIC

TITLE OF INVENTION: IMMUNE RESPONSE
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 4225 Executive Square, Suite 1400
CITY: La Jolla
STATE: California
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/09951
FILING DATE: 06-JUN-1996
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Learn, June M.
REGISTRATION NUMBER: 31,238
REFERENCE/DOCKET NUMBER: 07254/037W01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 678-5070
TELEFAX: (619) 678-5099
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
CLONE: HbcAg
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..15
PCT-US96-09951-7

Query Match 100.0%; Score 74; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.00028;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTPAYRPPNAPIL 13
Db 3 TTPAYRPPNAPIL 15

RESULT 13

US-09-100-409A-45
Sequence 45, Application US/09100409A
Patent No. 6090388
GENERAL INFORMATION:
APPLICANT: Wang, Chang Yi
TITLE OF INVENTION: PEPTIDE COMPOSITION FOR
PREVENTION AND TREATMENT OF HIV INFECTION AND
IMMUNE DISORDERS
NUMBER OF SEQUENCES: 64
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & FINNEGAN
STREET: 345 Park Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10154-0054
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version
#1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/100,409A

```
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME:
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: 1151-4154
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-758-4800
; TELEFAX: 212-751-6849
; INFORMATION FOR SEQ ID NO: 45:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-09-100-409A-45

Query Match 100.0%; Score 74; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.00039;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
Db 9 TPPAYRPPNPAPIL 21

RESULT 14
US-09-701-623C-69
; Sequence 69, Application US/09701623C
; Patent No. 6811782
; GENERAL INFORMATION:
; APPLICANT: Wang Ph.D., Chang Yi
; TITLE OF INVENTION: PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT OF
; FILE REFERENCE: 11514153US1
; CURRENT APPLICATION NUMBER: US/09/701,623C
; PRIOR FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: PCT/US99/13959
; PRIOR FILING DATE: 1999-06-21
; PRIOR APPLICATION NUMBER: 09/100,287
; PRIOR FILING DATE: 1998-06-20
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 69
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-701-623C-69

Query Match 100.0%; Score 74; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.00039;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
Db 9 TPPAYRPPNPAPIL 21

RESULT 15
PCT-US95-13841-13
; Sequence 13, Application PC/TUS9513841
; GENERAL INFORMATION:
; APPLICANT: United Biomedical Inc; Walfield, Alan M.;
; APPLICANT: Wang, Chang Yi
; TITLE OF INVENTION: Synthetic IgE Membrane Anchor
; TITLE OF INVENTION: Peptide Immunogens for the Treatment of Allergy
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Maria C.H. Lin
; STREET: 345 Park Avenue
; CITY: New York
```

```
; STATE: NY
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/13841
; FILING DATE: 25-OCT-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/328,519
; FILING DATE: 25-OCT-1994
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lin, Maria C.H.
; REGISTRATION NUMBER: 29,323
; REFERENCE/DOCKET NUMBER: 1151-4117
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-758-4800
; TELEFAX: 212-751-6849
; TELEX: 421792
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US95-13841-13

Query Match 100.0%; Score 74; DB 5; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.00039;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
Db 9 TPPAYRPPNPAPIL 21

Search completed: September 8, 2005, 03:06:03
Job time : 43 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 8, 2005, 03:01:30 ; Search time 163 Seconds
(without alignments)
31.409 Million cell updates/sec

Title: US-09-647-981A-10
Perfect score: 74
Sequence: 1 TPPAYRPPNAPIL 13

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1774312 seqs, 393823214 residues 1774312
Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	ID	Description
1	74	100.0	13	US-09-055-744-10
2	74	100.0	13	US-09-839-447A-86
3	74	100.0	13	US-09-277-074-9
4	74	100.0	13	US-09-277-064-9
5	74	100.0	13	US-09-788-110A-4
6	74	100.0	13	US-10-106-487-22
7	74	100.0	13	US-10-128-711-113
8	74	100.0	13	US-10-116-118-30
9	74	100.0	13	US-10-371-525-49
10	74	100.0	13	US-10-371-069-49
11	74	100.0	13	US-10-371-645-49

12	74	100.0	13	US-10-371-260-49	Sequence 49, Appl
13	74	100.0	13	US-10-372-735-55	Sequence 55, Appl
14	74	100.0	13	US-10-369-060A-86	Sequence 86, Appl
15	74	100.0	13	US-10-388-337-22	Sequence 22, Appl
16	74	100.0	13	US-10-608-541-50	Sequence 50, Appl
17	74	100.0	13	US-10-182-252A-1374	Sequence 1374, Ap
18	74	100.0	13	US-10-333-430-63	Sequence 63, Appl
19	74	100.0	13	US-10-808-681-5	Sequence 5, Appli
20	74	100.0	13	US-10-691-125-6	Sequence 6, Appli
21	74	100.0	13	US-10-470-045-31	Sequence 31, Appl
22	74	100.0	13	US-10-470-045-52	Sequence 52, Appl
23	74	100.0	13	US-10-491-008A-51	Sequence 51, Appl
24	74	100.0	13	US-11-055-119-80	Sequence 80, Appl
25	74	100.0	14	US-10-371-525-124	Sequence 124, App
26	74	100.0	14	US-10-371-069-124	Sequence 124, App
27	74	100.0	14	US-10-371-645-124	Sequence 124, App
28	74	100.0	14	US-10-371-260-124	Sequence 124, App
29	74	100.0	16	US-10-106-876-3	Sequence 3, Appli
30	74	100.0	18	US-10-106-876-10	Sequence 10, Appl
31	74	100.0	20	US-09-839-447A-107	Sequence 107, App
32	74	100.0	20	US-10-369-060A-107	Sequence 107, App
33	74	100.0	21	US-08-785-997-43	Sequence 43, Appl
34	74	100.0	21	US-09-387-340-43	Sequence 43, Appl
35	74	100.0	21	US-09-386-591-43	Sequence 43, Appl
36	74	100.0	21	US-10-732-862A-228	Sequence 228, App
37	74	100.0	23	US-10-128-711-114	Sequence 114, App
38	74	100.0	26	US-10-128-711-115	Sequence 115, App
39	74	100.0	32	US-10-732-862A-227	Sequence 227, App
40	74	100.0	80	US-10-371-525-22	Sequence 22, Appl
41	74	100.0	80	US-10-371-069-22	Sequence 22, Appl
42	74	100.0	80	US-10-371-645-22	Sequence 22, Appl
43	74	100.0	80	US-10-371-260-22	Sequence 22, Appl
44	74	100.0	118	US-10-371-525-8	Sequence 8, Appli
45	74	100.0	118	US-10-371-069-8	Sequence 8, Appli

ALIGNMENTS

RESULT 1
US-09-055-744-10
; Sequence 10, Application US/09055744
; Publication No. US20010019714A1
; GENERAL INFORMATION:
; APPLICANT: Sia, Charles
; APPLICANT: Chong, Pele
; APPLICANT: Klein, Michel
; TITLE OF INVENTION: HIV-SPECIFIC CYTOTOXIC T-CELL RESPONSES
; FILE REFERENCE: 1038-746
; CURRENT APPLICATION NUMBER: US/09/055,744
; CURRENT FILING DATE: 1998-04-07
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus type 1
US-09-055-744-10

Query Match 100.0%; Score 74; DB 9; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPPAYRPPNAPIL 13
Db 1 TPPAYRPPNAPIL 13

RESULT 2
US-09-839-447A-86
; Sequence 86, Application US/09839447A
; Patent No. US20020058247A1
; GENERAL INFORMATION:

```

; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Hepatitis B virus
US-09-277-064-9

Query Match      100.0%; Score 74; DB 10; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 TPPAYRPPNAPIL 13
Db      1 TPPAYRPPNAPIL 13

RESULT 5
US-09-788-110A-4
; Sequence 4, Application US/09788110A
; Publication No. US20040086518A1
; GENERAL INFORMATION:
; APPLICANT: Zanetti, Maurizio
; TITLE OF INVENTION: A Universal Vaccine and Method for Treating Cancer Employing
; TITLE OF INVENTION: Telomerase Reverse Transcriptase
; FILE REFERENCE: UCSD-07017
; CURRENT APPLICATION NUMBER: US/09/788.110A
; CURRENT FILING DATE: 2001-02-15
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-788-110A-4

Query Match      100.0%; Score 74; DB 11; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 TPPAYRPPNAPIL 13
Db      1 TPPAYRPPNAPIL 13

RESULT 6
US-10-106-487-22
; Sequence 22, Application US/10106487
; Publication No. US20020164721A1
; GENERAL INFORMATION:
; APPLICANT: FIRAT, HUSEYIN
; APPLICANT: LEMONNIER, FRANCOIS
; APPLICANT: LANGLADE-DEMOYEN, PIERRE
; APPLICANT: MICHEL, MARIE-LOUISE
; TITLE OF INVENTION: DESIGN OF A POLYPEPTOTIC CONSTRUCT FOR THE INDUCTION
; TITLE OF INVENTION: OF
; TITLE OF INVENTION: HLA-A2.1 RESTRICTED HIV 1 SPECIFIC CTL RESPONSES USING
; TITLE OF INVENTION: HHD MICE
; FILE REFERENCE: 03495.0196 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/10/106,487
; CURRENT FILING DATE: 2002-03-27
; PRIOR APPLICATION NUMBER: 09/675,673
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/158,356
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Hepatitis B virus
US-10-106-487-22

Query Match      100.0%; Score 74; DB 13; Length 13;

```


Best Local Similarity 100.0%; Pred. No. 0.0021; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
| | | | | | | | | |
Db 1 TPPAYRPPNAPIL 13

RESULT 7

US-10-128-711-113
; Sequence 113, Application US/10128711
; Publication No. US20030099634A1
; GENERAL INFORMATION:
; APPLICANT: VITIELLO, Maria A.
; CHESTNUT, Robert W.
; SETTE, Alessandro D.
; CELIS, Esteban
; GRAY, Howard
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
; CTL IMMUNITY
; NUMBER OF SEQUENCES: 153
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Townsend and Townsend Kourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/128,711
; FILING DATE: 22-Apr-2002
; CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/197,484
FILING DATE: 16-FEB-1994
APPLICATION NUMBER: US 07/935,811
FILING DATE: 26-AUG-1992
APPLICATION NUMBER: US 07/874,491
FILING DATE: 27-APR-1992
APPLICATION NUMBER: US 07/827,682
FILING DATE: 29-JAN-1992
APPLICATION NUMBER: US 07/749,568
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14137-26-4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 467-9600
TELEFAX: (206) 623-6793
INFORMATION FOR SEQ ID NO: 113:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 113:
US-10-128-711-113

Query Match 100.0%; Score 74; DB 14; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
| | | | | | | | | |
Db 1 TPPAYRPPNAPIL 13

RESULT 8

US-10-116-118-30
; Sequence 30, Application US/10116118
; Publication No. US20030143672A1
; GENERAL INFORMATION:
; APPLICANT: Tangri, Shabnam
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn
; APPLICANT: Fikes, John D.
; TITLE OF INVENTION: Heteroclitic Analogs and Related Methods
; FILE REFERENCE: 2060.0090003
; CURRENT APPLICATION NUMBER: US/10/116,118
; CURRENT FILING DATE: 2002-08-07
; PRIOR APPLICATION NUMBER: US 60/166,529
; PRIOR FILING DATE: 1999-11-18
; PRIOR APPLICATION NUMBER: US 60/239,008
; PRIOR FILING DATE: 2000-10-06
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: Patent In version 3.1
; SEQ ID NO 30
; LENGTH: 13
; TYPE: PPT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: (HBV core)
US-10-116-118-30

Query Match 100.0%; Score 74; DB 14; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
| | | | | | | | | |
Db 1 TPPAYRPPNAPIL 13

RESULT 9

US-10-371-525-49
; Sequence 49, Application US/10371525
; Publication No. US20030203869A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John D.
; APPLICANT: Hermanson, Gary G.
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn Y.
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert W.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Expression Vectors for Stimulating an
; REFERENCE/DOCKET NUMBER: 14137-26-4
; FILE REFERENCE: 39963-2022.01
; CURRENT APPLICATION NUMBER: US/10/371,525
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 09/311,784
; PRIOR FILING DATE: 1999-05-13
; PRIOR APPLICATION NUMBER: US 60/085,751
; PRIOR FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 49
; LENGTH: 13
; TYPE: PPT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: residues 128-141 of HBV core antigen (HBVcore 128)
US-10-371-525-49

Query Match 100.0%; Score 74; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13

```
; FEATURE:
; OTHER INFORMATION: residues 128-141 of HBV core antigen (HBVcore 128)
US-10-371-645-49

Query Match      100.0%; Score 74; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
Db 1 TPPAYRPPNPAPIL 13

RESULT 10
US-10-371-069-49
; Sequence 49, Application US/10371069
; Publication No. US20030216342A1
; GENERAL INFORMATION:
; APPLICANT: EPIMMUNE Inc.
; APPLICANT: Fikes, John D.
; APPLICANT: Hermanson, Gary G.
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn Y.
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert W.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Expression Vectors for Stimulating an
; TITLE OF INVENTION: Immune Response and Methods of Using the Same
; FILE REFERENCE: 39963-20022.10
; CURRENT APPLICATION NUMBER: US/10/371,069
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 09/078,904
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: US 60/085,751
; PRIOR FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 49
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: residues 128-141 of HBV core antigen (HBVcore 128)
US-10-371-069-49

Query Match      100.0%; Score 74; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
Db 1 TPPAYRPPNPAPIL 13

RESULT 11
US-10-371-645-49
; Sequence 49, Application US/10371645
; Publication No. US20030216343A1
; GENERAL INFORMATION:
; APPLICANT: EPIMMUNE Inc.
; APPLICANT: Fikes, John D.
; APPLICANT: Hermanson, Gary G.
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn Y.
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert W.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Expression Vectors for Stimulating an
; TITLE OF INVENTION: Immune Response and Methods of Using the Same
; FILE REFERENCE: 39963-20022.11
; CURRENT APPLICATION NUMBER: US/10/371,645
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 09/078,904
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: US 60/085,751
; PRIOR FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 49
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: residues 128-141 of HBV core antigen (HBVcore 128)
US-10-371-645-49

Query Match      100.0%; Score 74; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
Db 1 TPPAYRPPNPAPIL 13

RESULT 12
US-10-371-260-49
; Sequence 49, Application US/10371260
; Publication No. US20030220285A1
; GENERAL INFORMATION:
; APPLICANT: EPIMMUNE Inc.
; APPLICANT: Fikes, John D.
; APPLICANT: Hermanson, Gary G.
; APPLICANT: Sette, Alessandro
; APPLICANT: Ishioka, Glenn Y.
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert W.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Expression Vectors for Stimulating an
; TITLE OF INVENTION: Immune Response and Methods of Using the Same
; FILE REFERENCE: 39963-20022.13
; CURRENT APPLICATION NUMBER: US/10/371,260
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 09/078,904
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: US 60/085,751
; PRIOR FILING DATE: 1998-05-15
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 49
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: residues 128-141 of HBV core antigen (HBVcore 128)
US-10-371-260-49

Query Match      100.0%; Score 74; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNPAPIL 13
Db 1 TPPAYRPPNPAPIL 13

RESULT 13
US-10-372-735-55
; Sequence 55, Application US/10372735
; Publication No. US20030225251A1
; GENERAL INFORMATION:
; APPLICANT: Sallberg, Matti
; TITLE OF INVENTION: SPECIFICITY EXCHANGERS THAT REDIRECT
; TITLE OF INVENTION: ANTIBODIES TO A PATHOGEN
; FILE REFERENCE: TRIPEP.7AUC4CP1
; CURRENT APPLICATION NUMBER: US/10/372,735
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: 10/234,579
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 09/839,666
; PRIOR FILING DATE: 2001-04-19
; PRIOR APPLICATION NUMBER: 09/532,106
; PRIOR FILING DATE: 2000-03-21
; PRIOR APPLICATION NUMBER: 09/246,258
; PRIOR FILING DATE: 1999-02-08
```

; PRIOR APPLICATION NUMBER: 08/737,085
; PRIOR FILING DATE: 1996-12-27
; PRIOR APPLICATION NUMBER: PCT/SE95/00468
; PRIOR FILING DATE: 1995-04-27
; PRIOR APPLICATION NUMBER: 09/664,945
; PRIOR FILING DATE: 2000-09-19
; PRIOR APPLICATION NUMBER: 09/664,025
; PRIOR FILING DATE: 2000-09-19
; PRIOR APPLICATION NUMBER: PCT/IB01/02327
; PRIOR FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 10/153,271
; PRIOR FILING DATE: 2002-05-21
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 199
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificially Synthesized Peptides
US-10-372-735-55

Query Match 100.0%; Score 74; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
|||||
Db 1 TPPAYRPPNAPIL 13

RESULT 14

US-10-369-060A-86
; Sequence 86, Application US/10369060A
; Publication No. US20030235815A1
; GENERAL INFORMATION:
; APPLICANT: Sallberg, Matti
; TITLE OF INVENTION: SYNTHETIC PEPTIDES THAT BIND TO THE
; FILE REFERENCE: HEPATITIS B VIRUS CORE AND E ANTIGENS
; CURRENT APPLICATION NUMBER: US/10/369,060A
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: 09/839,447
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: 09/556,605
; PRIOR FILING DATE: 2000-04-21
; NUMBER OF SEQ ID NOS: 111
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 86
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Mus musculus
US-10-369-060A-86

Query Match 100.0%; Score 74; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
|||||
Db 1 TPPAYRPPNAPIL 13

RESULT 15

US-10-388-337-22
; Sequence 22, Application US/10388337
; Publication No. US20040018208A1
; GENERAL INFORMATION:
; APPLICANT: FIRAT, Huseyin
; APPLICANT: LEMONNIER, Francois

; APPLICANT: LANGLADE-DEMOYEN, Pierre
; APPLICANT: MICHEL, Marie-Louise
; APPLICANT: SUHRBIER, Andreas A
; TITLE OF INVENTION: HYBRID OR CHIMERIC POLYNUCLEOTIDES, PROTEINS, AND
; TITLE OF INVENTION: COMPOSITIONS COMPRISING HEPATITIS B VIRUS SEQUENCES
; FILE REFERENCE: 03495.0198 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/10/388,337
; CURRENT FILING DATE: 2003-03-14
; PRIOR APPLICATION NUMBER: US/09/671,198B
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: 60/156,945
; PRIOR FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Hepatitis B virus
US-10-388-337-22

Query Match 100.0%; Score 74; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPPAYRPPNAPIL 13
|||||
Db 1 TPPAYRPPNAPIL 13

Search completed: September 8, 2005, 03:17:07
Job time : 164 secs

This Page Blank (uspto)